Pharmaceutical companies are delaying the launch of new medicines in European markets as the industry faces mounting pressure from U.S. policies and pricing shifts under the Trump administration. The delays represent a strategic response to changing regulatory and economic conditions affecting global drug distribution.
The postponements come as pharmaceutical companies reassess their international launch strategies amid evolving U.S. healthcare policies. European patients may face longer wait times for accessing new treatments as companies prioritize markets based on pricing and regulatory considerations.